NovaBiotics' Lynovex shows efficacy as an adjunct in cystic fibrosis

A new study has demonstrated the activity of Scottish biotech company NovaBiotics’ candidate cystic fibrosis (CF) therapy candidate, Lynovex (NM001), within the physiological environment of CF sputum, including its ability to kill the emerging CF pathogen Mycobacterium abscessus.

The number of bacteria in sputum samples of 23 adult CF patients was measured before, and 24 hours after, exposure to Lynovex, with and without antibiotics frequently used to treat CF lung infections.

The results showed Lynovex’s ability to reduce sputum bacterial levels with only a few hours of exposure. It also outperformed tobramycin and ciprofloxacin, two commonly-used CF lung infection antibiotics in its ability to kill the complex mix of sputum bacteria within the samples. The combination of the two antibiotics plus Lynovex, however, was even more effective, which is significant since Lynovex is intended as an adjunct therapy.